XML 31 R16.htm IDEA: XBRL DOCUMENT

Convertible Note Payable	12 Months Ended
Convertible Note Payable	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible Note Payable	Convertible Note Payable In October 2012, in conjunction with our initial public offering the Post-IPO GSK Note was established in the principal amount of $5.4 million, with a maturity date of October 9, 2015. On January 29, 2015, the principal amount outstanding under the Post-IPO GSK Note of $5.4 million was converted into 1,356,738 shares of our common stock at a conversion price of $4.00 per share. We recorded a loss from the change in valuation of the convertible note payable of zero, $1.8 million and $12.1 million on the statements of operations and comprehensive loss for the years ended December 31, 2016, 2015 and 2014, respectively.